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Background: It is important to know and decide when to end regimen for the quality of life of the patients. However, there is 
currently no clear agreement on when to terminate palliative chemotherapy. We investigated the duration between the last 
chemotherapy and death, and associated factors aff  ecting patients receiving palliative care after the last chemotherapy.
Methods: We studied 242 patients who were put into palliative care ward after receiving chemotherapy and died during 
hospitalization from 2008 to 2009. Electronic medical records were used to gather information on demographic characteristics, 
types of primary cancer, and palliative chemotherapy. Th   en we analyzed the relationship between the clinical characteristics of 
patients and interval between last chemotherapy and death.
Results: The average survival time of patients after referral to palliative care was 17.5 days; survival time after discontinuation 
of chemotherapy was 103 days. Also, 104 (43.0%) patients died within 3 months and 14 (5.8%) patients died within 1 month of 
persistent palliative chemotherapy. Chemotherapy on patients within 3 months from their death was not associated with the 
social characteristics of the population.
Conclusion: Th   e patients who were referred to palliative care were found to have continued to receive chemotherapy within 3 
months before death. However, only a small number of patients received chemotherapy within 1 month before death, which 
confirms that futile chemotherapy that extends to the end of life was less frequent. Doctors should be able to recognize the 
implications of excessive and aggressive use of chemotherapy and should actively communicate with patients about therapeutic 
choices.
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INTRODUCTION
Th   e incidence of cancer in Korea has increased 3% per year 
from 1999 to 2007. About 160,000 new cancer cases occur every 
year and mortality rate exceeds 140 per 100,000 people.
1) Due 
to ongoing development of new ‘less toxic thus well tolerated’ 
drugs, anti-cancer chemotherapy until the end-of-life is gradually 
increasing.
2) However, an excessive chemotherapy can decrease 
the quality of life of patients. Th   erefore doctors should consider 
gain and loss of chemotherapy administered to terminally ill  Daeun Jung, et al: The Realities of Palliative Chemotherapy Near the End of Life
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patients in the palliative care ward; whether to enforce appropriate 
chemotherapy in a purpose of treating patients in palliative care 
ward need to be discussed.
3,4)
Thus it is important to know and decide when to end 
regimen for the quality of life of the patients. However, there is 
currently no clear agreement on when to terminate palliative 
chemotherapy. We therefore investigated the duration between 
the last chemotherapy and death, and associated factors aff  ecting 
patients receiving palliative care aft  er the last chemotherapy.
METHODS
1. Subjects
Subjects of this study are 309 patients who died during 
hospitalization in the palliative care ward in Samsung Medical 
Center from January 1, 2008 to May 31, 2009. Among these 
patients, 67 patients were excluded due to following reasons: 
2 patients were non-cancer terminal illness, 62 patients never 
received anti-cancer chemotherapy since diagnosis of cancer and 
3 patents has been initially registered in the palliative care ward 
then re-treated with anti-cancer chemotherapy. Thus electronic 
medical records of 242 patients have been studied in this 
investigation. These patients had been treated with anti-cancer 
chemotherapy more than once before referral to palliative care 
unit.
2. Data Collection
Throughout the retrospective investigation of electronic 
medical records, demographic characteristics such as age, sex 
and level of education were obtained along with the type of 
cancer, metastatic site, date of palliative care registration, Eastern 
Cooperative Oncology Group (ECOG) performance status 
upon the last hospitalization, date of death, number of palliative 
chemotherapy regimen, and the start and end date of the last 
chemotherapy regimen. We defined palliative chemotherapy 
as chemotherapy of which purpose is not to cure cancer but to 
relieve symptoms or to prolong life. End of chemotherapy is 
defi  ned as the last administration of anti-cancer drug. Th  e  period 
between the end of chemotherapy and death was calculated as 
the number of days.
ECOG performance is a tool to evaluate performance status 
of cancer patients. It is appraised in six grades: grade 0 (fully 
active), grade 1 (restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary 
nature), grade 2 (ambulatory and capable of all self-care but 
unable to carry out any work activities. Up about more than 
50% of waking hours), grade 3 (capable of only limited self-care; 
confined to bed or chair 50% or more of waking hours), grade 
4 (completely disabled; cannot carry on any self-care; totally 
confi  ned to bed or chair), grade 5 (death).
3. Statistical Analysis
To find out relationship between survival time since the 
last palliative chemotherapy and patient characteristics, t-test 
was used for parametric test and Mann-Whitney test was used 
for non-parametric test. To validate univariate analysis between 
groups according to the length of survival, chi-square test and 
Fisher’s exact test were used. PASW (old: SPSS) ver. 18.0 (SPSS 
Inc., Chicago, IL, USA) was used to analyze data. Two-tailed test 
were done and signifi  cance level was set for 0.05.
RESULTS
1. Baseline Characteristics of Study Subjects
Mean age of the study subjects was 58.5 (± 12.5) years. 
Median days from the end of chemotherapy to registration of 
palliative care were 64.5 days. Survival time after registration 
in palliative care was 17.5 days and survival time after the 
end of chemotherapy was 103 days. There were significant 
diff  erences between male and female in the number of palliative 
chemotherapy regimen, level of education, and religion. 
However there were no significant differences between male 
and female in length of palliative chemotherapy, period from 
the end of chemotherapy to the date of registration in palliative 
care, ECOG performance at the time of registration in palliative 
care, survival time aft  er the end of chemotherapy and length of 
survival after registration in palliative care. The highest number 
of patients suffered from gastrointestinal cancers including 
colorectal and stomach, which were 104 patients (43%), followed 
by 37 lung cancer patients (15.3%), 27 hepatobilliary cancer 
patients (11.2%) and 26 pancreatic cancer patients (10.7%) 
(Table 1). Three patients (1.2%) were treated with anti-cancer Daeun Jung, et al: The Realities of Palliative Chemotherapy Near the End of Life
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Table 1. Baseline characteristics.
Variables Total (n = 242) Male (n = 139) Female (n = 103) P-value
Age, mean (SD) (y) 58.5 (12.5) 60.9 (12.8) 55.3 (11.3) 0.001*
ECOG PS at the time of referral to palliative care  0.238
†
2 or under 77 (31.8) 40 (28.8) 37 (35.9)
3 or above 165 (68.2) 99 (71.2) 66 (64.1)
Primary cancer (no. %) ND
Colorectal cancer 56 (23.1) 32 (23.0) 24 (23.3)
Stomach cancer 48 (19.8) 30 (21.6) 18 (17.5)
Lung cancer 37 (15.3) 22 (15.8) 15 (14.6)
Hepatobiliary cancer 27 (11.2) 18 (12.9) 9 (8.7)
Pancreas cancer 26 (10.7) 18 (12.9) 8 (7.8)
Gynecologic malignancy 14 (5.8) 14 (13.6)
Breast cancer 10 (4.1) 10 (9.7)
Others 24 (10.0) 19 (13.7) 5 (4.9)
Education status  0.009
†
High school or under 134 (55.4) 67 (48.2) 67 (65.0)
College or above 108 (44.6) 72 (51.8) 36 (35.0)
Religion  0.004
‡
Have no religion 76 (31.4) 54 (38.8) 22 (21.4)
Protestant 68 (28.1) 28 (20.1) 40 (38.8)
Buddhism 51 (21.1) 30 (21.6) 21 (20.4)
Catholicism 41 (16.9) 22 (15.8) 19 (18.4)
Others 6 (2.5) 5 (3.6) 1 (1.0)
No. of palliative chemotherapy regimen 2 (1-12) 2 (1-8) 2 (1-12) 0.022
§
Duration of palliative chemotherapy (d) 288 (1-3,882) 289 (1-3,882) 282 (1-2,067) 0.258
§
Duration between last chemotherapy and referral to palliative care (d) 64.5 (4-1,880) 65.0 (4-703) 64.0 (9-1,880) 0.144
§
Duration between referral to palliative care and death (d) 17.5 (0-622) 17 (0-622) 21 (0-381) 0.491
§
Duration between last chemotherapy and death (d) 103 (7-2,350) 107 (7-2,350) 102 (13-592) 0.577
§
Frequency of chemotherapy near the end-of-life 
In the last 6 mo 182 (75.2) 108 (77.7) 74 (71.8) 0.252
†
In the last 3 mo 104 (43.0) 59 (42.4) 45 (43.7) 0.827
†
In the last 1 mo 14 (5.8) 9 (6.5) 5 (4.9) 0.585
†
In the last 2 wk 3 (1.2) 2 (1.4) 1 (1.0) 0.741
†
Values are presented as number (%) or median (range). 
ECOG PS: Eastern Cooperative Oncology Group performance status, ND: not done.
*P-value by t-test. 
†P-value by chi-square test. 
‡P-value by Fisher’s exact test. 
§P-value by Mann-Whitney test. Daeun Jung, et al: The Realities of Palliative Chemotherapy Near the End of Life
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chemotherapy within two weeks before death, 14 patients (5.8%) 
within one month, 104 patients (43.0%) within three months 
and a new regimen of anti-cancer drug was administered to a total 
of 56 patients (23.1%) within three months before death.
2. The Relationship between Patients’ 
Characteristics and Survival after the Last 
Chemotherapy
We analyzed the diff  erence of survival duration aft  er the last 
chemotherapy by the patients’ characteristics. There were no 
significant differences of survival duration in age, sex, religion, 
level of education, number of chemotherapy regimen, and type of 
cancer between the group who survived more than 90 days and 
the group who survived less than 90 days. However, 24 patients 
(23.1%) in the group who survived more than 90 days and 53 
patients (38.3%) in the group who survived less than 90 days had 
ECOG performance grade 2 or under on the day of registration 
at palliative care (χ
2 = 6.42, P = 0.011) (Table 2). This finding 
suggested that the patients having more survival duration had a 
relatively bett  er performance status, but there were no signifi  cant 
Table 2. Characteristics of patient who underwent chemotherapy in 3 months or less and more than 3 months before death.
Variables
Survival duration between last chemotherapy and death
≤90 day (n = 104) >90 day (n = 138) P-value*
Age (y)
<60 51 (49.0) 70 (50.7) 0.795
≥60 53 (51.0) 68 (49.3)
Sex
Male 59 (56.7) 80 (58.0) 0.847
Female 45 (43.3) 58 (42.0)
ECOG PS
2 or under 24 (23.1) 53 (38.4) 0.011
3 or above 80 (76.9) 85 (61.6)
Religion
Have no religion 29 (27.9) 47 (34.1) 0.306
With religion 75 (72.1) 91 (65.9)
Education status
High school or under 55 (52.9) 79 (57.2) 0.499
College or above 49 (47.1) 59 (42.8)
No. of palliative chemotherapy regimen, median (range)  2 (1-8)  2 (1-12)  0.729
†
Primary cancer
Stomach and colorectal 47 (45.2) 57 (41.3) 0.250
Hepatobiliary and pancreas 19 (18.3) 34 (24.6)
Lung 21 (20.2) 16 (11.6)
Breast  2 (1.9)  8 (5.8)
Gynecologic  6 (5.8)  8 (5.8)
Others  9 (8.7) 15 (10.9)
Values are presented as number (%).
ECOG PS: Eastern Cooperative Oncology Group performance status.
*P-value by chi-square test. 
†P-value by Mann-Whitney test.Daeun Jung, et al: The Realities of Palliative Chemotherapy Near the End of Life
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differences between better performance status group (ECOG 
2 or under) and poor performance status group (ECOG 3 or 
above) in terms of duration of palliative chemotherapy, number of 
chemotherapy regimen, duration from the last chemotherapy to 
referral to palliative care and survival duration aft  er referral (Table 
3).
DISCUSSION
We found that 43% of terminally ill patients have received 
chemotherapy within three months before death and 23% started 
new regimen of chemotherapy within three months before death. 
Th  ese  fi  ndings were similar to the other previous studies. Several 
studies have discussed chemotherapy near the end of life. Earle 
and the colleagues reported that 11.6% of 210,000 patients had 
received chemotherapy within two weeks before death
5) and 
Kao et al found that 8% and 18% of 750 terminally ill cancer 
patients had received chemotherapy within 2 weeks and 4 weeks 
before death, respectively.
6) In Korea, a retrospective multi-
center study showed that 43.9% and 30.9% of 3,750 patients 
had received chemotherapy within three and one month before 
death, respectively.
7) Another study by a tertiary care hospital in 
Seoul showed that 50.3% and 5.7% of 298 patients had received 
chemotherapy within 2 months and 2 weeks before death, 
respectively.
8) However, our study showed that 1.2 % of patients 
received chemotherapy within two weeks before death and 5.8% 
within one month before death, compared with the other study 
showing up to 20% of patients did so within 2 weeks before 
death.
9) This difference may be explained by the fact that our 
patients were referred to palliative care center thus treated less 
aggressively,
7,10) but the patients from other studies might not have 
an access to palliative care. We found that the patients referred to 
palliative care had few futile chemotherapy near the end of life. 
However, it remains to be confirmed whether this finding had 
some impact on improved survival or quality of life of patients.
Th   e previous studies showed various relationships between 
patient’s factors and persistent chemotherapy near the end 
of life and differed by socio-cultural conditions. Patients who 
were older, female, and had an access to palliative care, received 
less aggressive chemotherapy.
2) Married patients received less 
aggressive chemotherapy than unmarried patients.
5) Patients who 
were younger and had chemotherapy-sensitive tumors such as 
gastrointestinal cancer, received more aggressive chemotherapy. 
However, men rather than women received less aggressive 
chemotherapy.
6) Patients, who were symptomatic, under the 
age of 45 and were not referred to palliative care, were likely to 
continue receiving chemotherapy.
10) College graduate chose less 
aggressive treatment near the end of life in a study carried out in 
Korea,
7) but there were no relationship between educational level 
and choice of chemotherapy in terminally ill cancer patients in a 
study done in Netherlands.
11)
In this study, we could not find any association between 
chemotherapy near the end of life and many patient factors such 
as age, sex, religion, level of education, site of cancer and socio-
demographic factors only except performance status at the time 
of registration in palliative care. This could be explained by a 
small sample size. There were only 14 patients who underwent 
chemotherapy during the last month of life and the number 
of events was too small to find the related factors. Another 
Table 3. Status of palliative chemotherapy according to performance status.
ECOG PS ≤ 2 (n = 77) ECOG PS 3-4 (n = 165) P-value*
Duration of palliative chemotherapy (d) 257 (0-1,858) 300 (0-3,881) 0.435
No. of regimens  2 (1-12) 2 (1-10) 0.968
Duration between last palliative chemotherapy and referral 
to palliative care (d)
73 (4-1,728) 63 (4-1,880) 0.733
Duration between referral to palliative care and death (d) 16 (0-332) 18 (0-662) 0.837
Values are presented as median (range).
ECOG PS: Eastern Cooperative Oncology Group performance status.
*P-value by Mann-Whitney test. Daeun Jung, et al: The Realities of Palliative Chemotherapy Near the End of Life
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explanation is that the patients of our study already opted for 
palliative care. Selection of palliative care can be a strong factor to 
deny chemotherapy near the end of life. It is also consistent with a 
previous study on patients with metastatic cancer, which showed 
that patients considering a quality of life were likely to receive 
fewer chemotherapy and gett  ing chemotherapy had no signifi  cant 
association with gender, age, and level of education.
11)
We could not analyze the effect of physician factors on 
chemotherapy near the end of life, but the role of physician is 
important in doing aggressive chemotherapy until the end of life 
in Korea, considering that referral to palliative care is mostly done 
when there are no further chemotherapy options available.
12) 
One study reported that doctors felt uncomfortable in offering 
palliative care to advanced cancer patients but felt easier in 
discussing another chemotherapy options.
13) Also a study on 
95 incurable advanced cancer patients showed that only 39% 
of patients were told of their prognosis by their physician even 
though they were already getting palliative chemotherapy.
14) As 
physician’s lack of eff  ort to communicate with patients can cause 
futile chemotherapy near the end of life, further study is needed 
on the association of physician factors with chemotherapy near 
the end of life.
It is difficult to generalize our findings as this was a 
retrospective study conducted at a single tertiary hospital. 
Another limitation of this study is that impact of chemotherapy 
near the end of life on the quality of life cannot be evaluated 
directly. However, several studies have already reported that 
there was more harm in doing chemotherapy near the end of 
life.
3,4) Also we could not obtain objective data on purpose and 
effectiveness of palliative chemotherapy as wells as reason for 
starting or continuation of chemotherapy, thus it was impossible 
to assess whether the chemotherapy were appropriate or 
excessive.
Nevertheless, this study has advantages as it examined 
patients receiving palliative care and discussed differences 
with other existing studies. The existing studies reported that 
availability of palliative care
2) or providing information on 
palliative care
10) played an important role in patient’s decision-
making on treatment and reduced likelihood of receiving 
aggressive chemotherapy. Th   us it is thought to be meaningful to 
find out current situation of chemotherapy near the end of life 
among the patients at palliative care unit.
In conclusion, authors found there was no difference 
on administration of chemotherapy within 3 months before 
death between palliative care group in this study and usual care 
group from other studies. However, less chemotherapy were 
administered to the patients within one month before death in 
this study. It is postulated that earlier referral to palliative care 
would add survival duration without aggressive chemotherapy 
and thus improve patient’s quality of life. Eff  ectiveness of palliative 
care should be confirmed in randomized controlled study 
comparing survival and quality of life among incurable advanced 
cancer patients undergoing palliative chemotherapy with or 
without palliative care service. In addition, awareness and att  itude 
of each patient are more important than socio-demographic 
characteristics in decision-making of chemotherapy near the end 
of life and this can be aff  ected by proper communication between 
heath care professionals and patients regarding to purpose, 
benefits and harms of treatment. This also suggests a need for 
future study to identify a relationship of proper communication 
and patient’s quality of life.
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